[Correspondence] Reassessing antimalarial use in long-term SLE clinical trials
We read with interest the TULIP-LTE study by Vibeke Strand and colleagues1 evaluating the long-term effect of anifrolumab on patient-reported […]
The Lancet
The Lancet
Category Added in a WPeMatico Campaign
The Lancet
[Editorial] The evolving treatment landscape in Still’s disease
Although the treatment landscape in Still’s disease has seen substantial advances in recent decades, macrophage activation syndrome (MAS) continues to
The Lancet
[Comment] The brain as a window into rheumatoid arthritis stratified medicine?
TNF inhibitors have transformed outcomes for many, but not all, people with rheumatoid arthritis. Their approval in the late 1990s
The Lancet
[Comment] Polymyalgia rheumatica: killing them softly
Polymyalgia rheumatica has long been neglected, especially when it comes to pharmaceutical development: but why? In 2025, polymyalgia rheumatica should
The Lancet
[Comment] One step closer to predicting autoimmune congenital heart block?
Autoimmune congenital heart block occurs in around 1–2% of anti-Sjögren’s syndrome-related antigen A (SSA)/Ro antibody-positive pregnancies.1 Despite the rarity of